Grant A Mcarthur

List of Publications by Year in Descending Order

145 papers	36,378 citations	56 h-index	153 g-index
153 ext. papers	42,465 ext. citations	11.2 avg, IF	6.64 L-index

#	Paper	IF	Citations
145	Harnessing the immunotherapeutic potential of CDK4/6 inhibitors in melanoma: is timing everything?. *Npj Precision Oncology*, **2022**, 6, 26	9.8	0
144	Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. *Journal of Clinical Oncology*, **2021**, JCO2102229	2.2	39
143	Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES) **2021**, 9,		5
142	T Cells in Merkel Cell Carcinomas Have a Proinflammatory Profile Prognostic of Patient Survival. *Cancer Immunology Research*, **2021**, 9, 612-623	12.5	3
141	Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma. *Frontiers in Immunology*, **2021**, 12, 661737	8.4	7
140	CDK4/6 Inhibition Promotes Antitumor Immunity through the Induction of T-cell Memory. *Cancer Discovery*, **2021**, 11, 2582-2601	24.4	12
139	5-Year Outcomes with Cobimetinib plus Vemurafenib in Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study. *Clinical Cancer Research*, **2021**,	12.9	10
138	Combined BRAF, MEK, and CDK4/6 Inhibition Depletes Intratumoral Immune-Potentiating Myeloid Populations in Melanoma. *Cancer Immunology Research*, **2021**, 9, 136-146	12.5	7
137	An inverse stage-shift model to estimate the excess mortality and health economic impact of delayed access to cancer services due to the COVID-19 pandemic. *Asia-Pacific Journal of Clinical Oncology*, **2021**, 17, 359-367	1.9	27
136	Decline in cancer pathology notifications during the 2020 COVID-19-related restrictions in Victoria. *Medical Journal of Australia*, **2021**, 214, 281-283	4	14
135	Is resistance to targeted therapy in cancer inevitable?. *Cancer Cell*, **2021**, 39, 1047-1049	24.3	1
134	Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases. *European Journal of Cancer*, **2021**, 156, 149-163	7.5	2
133	Enhancing Adoptive Cell Transfer with Combination BRAF-MEK and CDK4/6 Inhibitors in Melanoma.. *Cancers*, **2021**, 13,	6.6	2
132	High-resolution MRI demonstrates that more than 90% of small intracranial melanoma metastases develop in close relationship to the leptomeninges. *Neuro-Oncology*, **2020**, 22, 423-432	1	3
131	Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma **2020**, 8,		9
130	Co-targeting bromodomain and extra-terminal proteins and MCL1 induces synergistic cell death in melanoma. *International Journal of Cancer*, **2020**, 147, 2176-2189	7.5	10
129	Clinical, FDG-PET and molecular markers of immune checkpoint inhibitor response in patients with metastatic Merkel cell carcinoma **2020**, 8,		5

128	A Distinct Pretreatment Immune Gene Signature in Lentigo Maligna Is Associated with Imiquimod Response. *Journal of Investigative Dermatology*, **2020**, 140, 869-877.e16	4.3	5
127	Lymphatic and Hematogenous Dissemination in Patients With Primary Cutaneous Melanoma. *JAMA Dermatology*, **2019**, 155, 1322	5.1	
126	Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. *New England Journal of Medicine*, **2019**, 381, 1535-1546	59.2	1260
125	Molecular Genomic Profiling of Melanocytic Nevi. *Journal of Investigative Dermatology*, **2019**, 139, 1762-1768	4.3	36
124	A novel immunogenic mouse model of melanoma for the preclinical assessment of combination targeted and immune-based therapy. *Scientific Reports*, **2019**, 9, 1225	4.9	8
123	Changes in long-range rDNA-genomic interactions associate with altered RNA polymerase II gene programs during malignant transformation. *Communications Biology*, **2019**, 2, 39	6.7	18
122	Bevacizumab as a steroid-sparing agent during immunotherapy for melanoma brain metastases: A case series. *Health Science Reports*, **2019**, 2, e115	2.2	12
121	Concordance of somatic mutational profile in multiple primary melanomas. *Pigment Cell and Melanoma Research*, **2018**, 31, 592-603	4.5	1
120	Exploring the feasibility and utility of exome-scale tumour sequencing in a clinical setting. *Internal Medicine Journal*, **2018**, 48, 786-794	1.6	3
119	Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance. *International Journal of Cancer*, **2018**, 142, 2139-2152	7.5	41
118	Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. *Lancet Oncology, The*, **2018**, 19, 672-681	21.7	512
117	Primary Tumor Thickness is a Prognostic Factor in Stage IV Melanoma: A Retrospective Study of Primary Tumor Characteristics. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2018**, 41, 90-94	2.7	7
116	Omitting radiosurgery in melanoma brain metastases: a drastic and dangerous de-escalation - Authors' reply. *Lancet Oncology, The*, **2018**, 19, e367	21.7	4
115	A phase I study of panobinostat in pediatric patients with refractory solid tumors, including CNS tumors. *Cancer Chemotherapy and Pharmacology*, **2018**, 82, 493-503	3.5	14
114	Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series. *European Journal of Cancer*, **2018**, 105, 88-102	7.5	37
113	Tumour mutation status and melanoma recurrence following a negative sentinel lymph node biopsy. *British Journal of Cancer*, **2018**, 118, 1289-1295	8.7	7
112	The Advantages and Challenges of Using FDG PET/CT for Response Assessment in Melanoma in the Era of Targeted Agents and Immunotherapy. *European Journal of Nuclear Medicine and Molecular Imaging*, **2017**, 44, 67-77	8.8	84
111	Combined CDK4/6 and PI3K Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer. *Cancer Research*, **2017**, 77, 6340-6352	10.1	99

110	Circulating Tumor DNA Analysis and Functional Imaging Provide Complementary Approaches for Comprehensive Disease Monitoring in Metastatic Melanoma.. *JCO Precision Oncology*, **2017**, 1, 1-14	3.6	25
109	Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. *New England Journal of Medicine*, **2017**, 377, 1345-1356	59.2	2030
108	Clinical and palliative care outcomes for patients of poor performance status treated with antiprogrammed death-1 monoclonal antibodies for advanced melanoma. *Asia-Pacific Journal of Clinical Oncology*, **2017**, 13, 385-390	1.9	24
107	Tumour mutation status and sites of metastasis in patients with cutaneous melanoma. *British Journal of Cancer*, **2017**, 117, 1026-1035	8.7	33
106	Management of Melanoma **2017**, 15-23		
105	Pathology of Melanoma **2017**, 9-13		
104	Combination Anti-CTLA-4 and Anti-RANKL in Metastatic Melanoma. *Journal of Clinical Oncology*, **2016**, 34, e104-6	2.2	46
103	Integration of Immuno-Oncology and Palliative Care. *Journal of Clinical Oncology*, **2016**, 34, 1561-2	2.2	9
102	Melanoma: the intersection of molecular targeted therapy and immune checkpoint inhibition. *Current Opinion in Immunology*, **2016**, 39, 30-8	7.8	18
101	Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma. *Cancer Discovery*, **2016**, 6, 59-70	24.4	73
100	Glucocorticoids did not reverse type 1 diabetes mellitus secondary to pembrolizumab in a patient with metastatic melanoma. *BMJ Case Reports*, **2016**, 2016,	0.9	42
99	Desmoglein 2 promotes vasculogenic mimicry in melanoma and is associated with poor clinical outcome. *Oncotarget*, **2016**, 7, 46492-46508	3.3	29
98	Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling. *Oncotarget*, **2016**, 7, 49800-49818	3.3	62
97	BRAF Inhibition in BRAFV600E-Positive Anaplastic Thyroid Carcinoma. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2016**, 14, 249-54	7.3	35
96	Targeting metabolic reprogramming as a potential therapeutic strategy in melanoma. *Pharmacological Research*, **2016**, 107, 42-47	10.2	24
95	Cell Cycle Regulation and Melanoma. *Current Oncology Reports*, **2016**, 18, 34	6.3	32
94	A community-based model of rapid autopsy in end-stage cancer patients. *Nature Biotechnology*, **2016**, 34, 1010-1014	44.5	46
93	The state of melanoma: challenges and opportunities. *Pigment Cell and Melanoma Research*, **2016**, 29, 404-16	4.5	63

92	Phenotype switching in melanoma: implications for progression and therapy. *Frontiers in Oncology*, **2015**, 5, 31	5.3	111
91	Ubiquitous expression of the Pik3caH1047R mutation promotes hypoglycemia, hypoinsulinemia, and organomegaly. *FASEB Journal*, **2015**, 29, 1426-34	0.9	17
90	Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib. *European Journal of Cancer*, **2015**, 51, 852-60	7.5	21
89	Adjuvant immunotherapy for cancer: the next step. *Lancet Oncology, The*, **2015**, 16, 478-80	21.7	9
88	Radiotherapy complements immune checkpoint blockade. *Cancer Cell*, **2015**, 27, 437-8	24.3	45
87	Low-dose cyclophosphamide enhances antigen-specific CD4(+) T cell responses to NY-ESO-1/ISCOMATRIX® vaccine in patients with advanced melanoma. *Cancer Immunology, Immunotherapy*, **2015**, 64, 507-18	7.4	24
86	Novel combination therapies for BRAF-mutant melanoma. *Journal of Translational Medicine*, **2015**, 13, K6	8.5	78
85	Melanoma. *Nature Reviews Disease Primers*, **2015**, 1, 15003	51.1	283
84	Cell cycle control as a promising target in melanoma. *Current Opinion in Oncology*, **2015**, 27, 141-50	4.2	52
83	The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma. *Science Signaling*, **2015**, 8, ra82	8.8	82
82	CDK4 inhibitors an emerging strategy for the treatment of melanoma. *Melanoma Management*, **2015**, 2, 255-266	2.1	10
81	Combination Therapies to Inhibit the RAF/MEK/ERK Pathway in Melanoma: We are not Done Yet. *Frontiers in Oncology*, **2015**, 5, 161	5.3	22
80	Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. *New England Journal of Medicine*, **2015**, 373, 23-34	59.2	5047
79	UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas. *Cancer Research*, **2015**, 75, 5228-34	10.1	196
78	Whole exome sequencing identifies a recurrent RQCD1 P131L mutation in cutaneous melanoma. *Oncotarget*, **2015**, 6, 1115-27	3.3	22
77	Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. *New England Journal of Medicine*, **2014**, 371, 1867-76	59.2	1403
76	Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. *Cancer Discovery*, **2014**, 4, 423-33	24.4	180
75	Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. *Lancet Oncology, The*, **2014**, 15, 954-65	21.7	197

74	Sequence artefacts in a prospective series of formalin-fixed tumours tested for mutations in hotspot regions by massively parallel sequencing. *BMC Medical Genomics*, **2014**, 7, 23	3.7	170
73	Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. *Lancet Oncology, The*, **2014**, 15, 323-32	21.7	753
72	Co-targeting deoxyribonucleic acid-dependent protein kinase and poly(adenosine diphosphate-ribose) polymerase-1 promotes accelerated senescence of irradiated cancer cells. *International Journal of Radiation Oncology Biology Physics*, **2014**, 88, 385-94	4	15
71	Preclinical FLT-PET and FDG-PET imaging of tumor response to the multi-targeted Aurora B kinase inhibitor, TAK-901. *Nuclear Medicine and Biology*, **2014**, 41, 148-54	2.1	10
70	The drug vehicle and solvent N-methylpyrrolidone is an immunomodulator and antimyeloma compound. *Cell Reports*, **2014**, 7, 1009-19	10.6	24
69	Bioinformatics pipelines for targeted resequencing and whole-exome sequencing of human and mouse genomes: a virtual appliance approach for instant deployment. *PLoS ONE*, **2014**, 9, e95217	3.7	15
68	Ipilimumab in pretreated patients with unresectable or metastatic cutaneous, uveal and mucosal melanoma. *Medical Journal of Australia*, **2014**, 201, 49-53	4	44
67	Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines. *Pigment Cell and Melanoma Research*, **2014**, 27, 590-600	4.5	133
66	Targeted therapies for cutaneous melanoma. *Hematology/Oncology Clinics of North America*, **2014**, 28, 491-505	3.1	10
65	Targeting the nucleolus for cancer-specific activation of p53. *Drug Discovery Today*, **2014**, 19, 259-65	8.8	34
64	A phase I study of panobinostat in pediatric patients with refractory solid tumors, including CNS tumors.. *Journal of Clinical Oncology*, **2014**, 32, 10061-10061	2.2	3
63	Randomized, double-blind phase II trial of NY-ESO-1 ISCOMATRIX vaccine and ISCOMATRIX adjuvant alone in patients with resected stage IIc, III, or IV malignant melanoma.. *Journal of Clinical Oncology*, **2014**, 32, 9050-9050	2.2	4
62	TRIM16 inhibits proliferation and migration through regulation of interferon beta 1 in melanoma cells. *Oncotarget*, **2014**, 5, 10127-39	3.3	28
61	The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma. *Clinical Cancer Research*, **2013**, 19, 5320-8	12.9	182
60	Targeting oncogenic drivers and the immune system in melanoma. *Journal of Clinical Oncology*, **2013**, 31, 499-506	2.2	82
59	Dysregulation of the basal RNA polymerase transcription apparatus in cancer. *Nature Reviews Cancer*, **2013**, 13, 299-314	31.3	147
58	Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. *Journal of Clinical Oncology*, **2013**, 31, 1767-74	2.2	295
57	BRAF-targeted therapy and immune responses to melanoma. *OncoImmunology*, **2013**, 2, e24462	7.2	11

56	Impact of MET expression on outcome in BRAF(V600E/K) advanced melanoma. *Histopathology*, **2013**, 63, 351-61	7.3	12
55	BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage. *Clinical Cancer Research*, **2013**, 19, 4589-98	12.9	102
54	Targeted-capture massively-parallel sequencing enables robust detection of clinically informative mutations from formalin-fixed tumours. *Scientific Reports*, **2013**, 3, 3494	4.9	38
53	Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. *Journal of Clinical Investigation*, **2013**, 123, 1371-81	15.9	226
52	Evaluation of cyclophosphamide as an immune enhancer for the NY-ESO-1/ISCOMATRIX vaccine in patients with metastatic melanoma.. *Journal of Clinical Oncology*, **2013**, 31, 3093-3093	2.2	
51	The current state of targeted therapy in melanoma: this time it's personal. *Seminars in Oncology*, **2012**, 39, 204-14	5.5	22
50	Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. *New England Journal of Medicine*, **2012**, 366, 707-14	59.2	1697
49	RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. *New England Journal of Medicine*, **2012**, 366, 207-15	59.2	838
48	The coming of age of MEK. *Lancet Oncology, The*, **2012**, 13, 744-5	21.7	6
47	Molecular therapeutic advances in personalized therapy of melanoma and non-small cell lung cancer. *Journal of Personalized Medicine*, **2012**, 2, 35-49	3.6	6
46	Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53. *Cancer Cell*, **2012**, 22, 51-65	24.3	368
45	Targeting NRAS in melanoma. *Cancer Journal (Sudbury, Mass.)*, **2012**, 18, 132-6	2.2	51
44	Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. *Journal of Clinical Oncology*, **2012**, 30, 2375-83	2.2	175
43	RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. *Journal of Clinical Oncology*, **2012**, 30, 316-21	2.2	318
42	Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. *Journal of Clinical Oncology*, **2012**, 30, 1628-34	2.2	141
41	Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma.. *Journal of Clinical Oncology*, **2012**, 30, 8502-8502	2.2	65
40	Analysis of molecular mechanisms of response and resistance to vemurafenib (vem) in BRAFV600E melanoma.. *Journal of Clinical Oncology*, **2012**, 30, 8503-8503	2.2	14
39	An open-label, multicenter safety study of vemurafenib (PLX4032, RO5185426) in patients with metastatic melanoma.. *Journal of Clinical Oncology*, **2012**, 30, 8517-8517	2.2	7

38	Clinical significance of genomic alterations of the CDK4-pathway and sensitivity to the CDK4 inhibitor PD 0332991 in melanoma.. *Journal of Clinical Oncology*, **2012**, 30, 8520-8520	2.2	9
37	Improved survival with vemurafenib in melanoma with BRAF V600E mutation. *New England Journal of Medicine*, **2011**, 364, 2507-16	59.2	5851
36	Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma. *Pigment Cell and Melanoma Research*, **2011**, 24, 666-72	4.5	168
35	Review: mucosal melanoma of the head and neck. *Melanoma Research*, **2011**, 21, 257-66	3.3	66
34	c-MYC coordinately regulates ribosomal gene chromatin remodeling and Pol I availability during granulocyte differentiation. *Nucleic Acids Research*, **2011**, 39, 3267-81	20.1	76
33	AKT promotes rRNA synthesis and cooperates with c-MYC to stimulate ribosome biogenesis in cancer. *Science Signaling*, **2011**, 4, ra56	8.8	104
32	Inhibition of RNA Polymerase I Transcription by CX-5461 As a Therapeutic Strategy for the Cancer-Specific Activation of p53 in MLL-Rearranged Acute Myeloid Leukemias. *Blood*, **2011**, 118, 1548-1548	2.2	2
31	Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. *Nature*, **2010**, 467, 596-9	50.4	1379
30	Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. *Nature*, **2010**, 468, 973-7	50.4	1678
29	Inhibition of mutated, activated BRAF in metastatic melanoma. *New England Journal of Medicine*, **2010**, 363, 809-19	59.2	2871
28	Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure. *Pigment Cell and Melanoma Research*, **2010**, 23, 210-5	4.5	88
27	Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. *Cancer Cell*, **2010**, 18, 683-95	24.3	1007
26	BRAF, a target in melanoma: implications for solid tumor drug development. *Cancer*, **2010**, 116, 4902-13	6.4	92
25	Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma. *Clinical Cancer Research*, **2009**, 15, 2166-73	12.9	111
24	Splicing the way to leukemia with KIT. *Leukemia and Lymphoma*, **2008**, 49, 1431-2	1.9	1
23	Imatinib as effective therapy for dermatofibrosarcoma protuberans: proof of concept of the autocrine hypothesis for cancer. *Future Oncology*, **2008**, 4, 211-7	3.6	10
22	The promise of PET in clinical management and as a sensitive test for drug cytotoxicity in sarcomas. *Expert Review of Molecular Diagnostics*, **2008**, 8, 105-19	3.8	6
21	Correlation of subjective self-reported melanoma growth rate with objective tumor proliferation markers. *Archives of Dermatology*, **2008**, 144, 555-6		11

20	Consensus approaches to best practice management of gastrointestinal stromal tumors. *Asia-Pacific Journal of Clinical Oncology*, **2008**, 4, 188-198	1.9	3
19	Sunitinib malate in the treatment of renal cell carcinoma and gastrointestinal stromal tumor: Recommendations for patient management*. *Asia-Pacific Journal of Clinical Oncology*, **2007**, 3, 167-176	1.9	10
18	Dermatofibrosarcoma protuberans: recent clinical progress. *Annals of Surgical Oncology*, **2007**, 14, 2876-86	3.1	103
17	Multi-tracer small animal PET imaging of the tumour response to the novel pan-Erb-B inhibitor CI-1033. *European Journal of Nuclear Medicine and Molecular Imaging*, **2006**, 33, 441-52	8.8	36
16	Rate of growth in melanomas: characteristics and associations of rapidly growing melanomas. *Archives of Dermatology*, **2006**, 142, 1551-8		226
15	Cyclin-dependent kinase 2 functions in normal DNA repair and is a therapeutic target in BRCA1-deficient cancers. *Cancer Research*, **2006**, 66, 8219-26	10.1	104
14	Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. *Lancet, The*, **2006**, 368, 1329-38	40	2004
13	Dermatofibrosarcoma protuberans: a surgical disease with a molecular savior. *Current Opinion in Oncology*, **2006**, 18, 341-6	4.2	36
12	Negative cell-cycle regulators cooperatively control self-renewal and differentiation of haematopoietic stem cells. *Nature Cell Biology*, **2005**, 7, 172-8	23.4	95
11	Cell division and hematopoietic stem cells: not always exhausting. *Cell Cycle*, **2005**, 4, 893-6	4.7	13
10	Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. *Journal of Clinical Oncology*, **2005**, 23, 866-73	2.2	374
9	Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 10697-702	11.5	373
8	MAD1 and c-MYC regulate UBF and rDNA transcription during granulocyte differentiation. *EMBO Journal*, **2004**, 23, 3325-35	13	153
7	Molecularly targeted treatment for dermatofibrosarcoma protuberans. *Seminars in Oncology*, **2004**, 31, 30-6	5.5	57
6	EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Epidermal growth factor receptor. *International Journal of Radiation Oncology Biology Physics*, **2003**, 55, 713-23	4	91
5	In response to Drs. Krause, Baumann, and Thames. *International Journal of Radiation Oncology Biology Physics*, **2003**, 57, 301	4	
4	mTOR-dependent regulation of ribosomal gene transcription requires S6K1 and is mediated by phosphorylation of the carboxy-terminal activation domain of the nucleolar transcription factor UBF. *Molecular and Cellular Biology*, **2003**, 23, 8862-77	4.8	349
3	Applications of positron emission tomography in the development of molecular targeted cancer therapeutics. *BioDrugs*, **2003**, 17, 339-54	7.9	16

2	MAD1 and p27(KIP1) cooperate to promote terminal differentiation of granulocytes and to inhibit Myc expression and cyclin E-CDK2 activity. *Molecular and Cellular Biology*, **2002**, 22, 3014-23	4.8	56
1	An inverse stage-shift model to estimate the excess mortality and health economic impact of delayed access to cancer services due to the COVID-19 pandemic		4